Axol Bioscience Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
49
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.2M
- Investors
-
12
Axol Bioscience General Information
Description
Operator of a biotechnology company intended for medical research, disease modeling, and drug development. The company generates stem cells from blood and tissue cells, extracted from healthy and diseased patients with the aim to develop the best human cell biology research tools to advance medical research and drug discovery for many of the world's biggest and best-known pharma companies and research institutions, enabling researchers to develop treatments based on stem cell research.
Contact Information
Website
www.axolbio.comCorporate Office
- Roslin Innovation Centre, Charnock Bradley Building
- Easter Bush Campus, Easter Bush
- Roslin EH25 9RG
- Scotland, United Kingdom
Corporate Office
- Roslin Innovation Centre, Charnock Bradley Building
- Easter Bush Campus, Easter Bush
- Roslin EH25 9RG
- Scotland, United Kingdom
Axol Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 07-Apr-2022 | $4.2M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 17-Mar-2021 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 16-Aug-2017 | Completed | Generating Revenue | |||
| 4. Equity Crowdfunding | 24-Mar-2016 | Completed | Generating Revenue | |||
| 3. Seed Round | 04-Jun-2015 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 21-Aug-2014 | $1.35M | $1.53M | Completed | Generating Revenue | |
| 1. Angel (individual) | 01-Jan-2013 | $185K | $185K | Completed | Startup |
Axol Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Ordinary | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 65,645 | $0.130441 | $2.38 | $2.38 | 1x | $2.38 | 0.54% | |
| Ordinary Shares | 87,500 | $0.130441 | $0.97 | $0.97 | 1x | $0.97 | 0.72% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Axol Bioscience Comparisons
Industry
Financing
Details
Axol Bioscience Competitors (34)
One of Axol Bioscience’s 34 competitors is StemCell Technologies, a Private Debt Financed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| StemCell Technologies | Private Debt Financed | Vancouver, Canada | ||||
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | ||||
| Cell Applications | Corporation | San Diego, CA | ||||
| MORAGA BIOTECHNOLOGY CORPORATION | Corporation | Los Angeles, CA | ||||
| AllCells | Private Equity-Backed | Alameda, CA |
Axol Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Axol Bioscience Patents
Axol Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201420853-D0 | Methods for differentiation of primate pluripotent stem cells | Inactive | 24-Nov-2014 | ||
| GB-201317657-D0 | Methods for differentiation of primate pluripotent stem cells | Inactive | 07-Oct-2013 |
Axol Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Axol Bioscience Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cleevely & Partners | Venture Capital | Minority | ||
| EMV Capital (Acquired) | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Meltwind Advisory | Venture Capital | Minority | ||
| Calculus Capital | PE/Buyout | Minority |
Axol Bioscience Investments & Acquisitions (2)
Axol Bioscience’s most recent deal was a Merger/Acquisition with Phenocell. The deal was made on 21-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Phenocell | 21-Oct-2024 | Merger/Acquisition | Biotechnology | ||
| Censo Biotechnologies | 17-Mar-2021 | Buyout/LBO | Biotechnology |
Axol Bioscience Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Phenocell | France | 2013 |
Axol Bioscience FAQs
-
When was Axol Bioscience founded?
Axol Bioscience was founded in 2012.
-
Where is Axol Bioscience headquartered?
Axol Bioscience is headquartered in Roslin, United Kingdom.
-
What is the size of Axol Bioscience?
Axol Bioscience has 49 total employees.
-
What industry is Axol Bioscience in?
Axol Bioscience’s primary industry is Biotechnology.
-
Is Axol Bioscience a private or public company?
Axol Bioscience is a Private company.
-
What is Axol Bioscience’s current revenue?
The current revenue for Axol Bioscience is .
-
How much funding has Axol Bioscience raised over time?
Axol Bioscience has raised $17M.
-
Who are Axol Bioscience’s investors?
Cleevely & Partners, EMV Capital (Acquired), , Meltwind Advisory, and Calculus Capital are 5 of 12 investors who have invested in Axol Bioscience.
-
Who are Axol Bioscience’s competitors?
StemCell Technologies, Novus Biologicals, Cell Applications, MORAGA BIOTECHNOLOGY CORPORATION, and AllCells are some of the 34 competitors of Axol Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
